In Brief: SmithKline Beecham's Bradycor
Executive Summary
SmithKline Beecham's Bradycor: Cortech announces suspension of SB's initiation of Phase II trials of Bradycor (SB-238,592), a bradykinin antagonist for treatment of traumatic brain injury, due to adverse effects observed in rat studies. The delay will allow for completion and analysis of additional animal studies...